Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2018 Filed May 29, 2018 23:00 UTC |
VAN OORT DOUGLAS MChairman and CEO
|
Exercise / conversionRestricted Stock · Derivative | 65,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · derivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,362 Underlying: Common Stock · 65,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: Restricted stock will vest as follows; 65,680 shares vested on May 25, 2018 and 65,681 shares will vest on May 25, 2019 and 2020. F5 · derivative.expiration_date: The shares of restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:00 UTC |
VAN OORT DOUGLAS MChairman and CEO
|
Tax withholdingCommon Stock | 21,904 | $11.57 | $253,429.28 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,761 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2018 vesting of restricted stock. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:00 UTC |
VAN OORT DOUGLAS MChairman and CEO
|
Exercise / conversionCommon Stock | 65,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000032 · wf-form4_152763484053208.xml · nonDerivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:57 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionRestricted Stock · Derivative | 8,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000030 · wf-form4_152763457965512.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting. F2 · derivative.exercise_date: Restricted stock will vest as follows; 8,333 shares vested on May 25, 2018, 8,333 shares will vest on May 25, 2019 and 8,334 shares will vest on May 25, 2020. F3 · derivative.expiration_date: These restricted shares will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:57 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000030 · wf-form4_152763457965512.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:51 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionRestricted Stock · Derivative | 6,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000028 · wf-form4_152763425350108.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 6,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting. F5 · derivative.exercise_date: Restricted stock will vest as follows; 6,666 units vested on May 25, 2018 and 6,667 units will vest on May 25, 2019 and 2020. F6 · derivative.expiration_date: These restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:51 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000028 · wf-form4_152763425350108.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:36 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionRestricted Stock · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000026 · wf-form4_152763335346523.xml · derivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Restricted stock will vest as follows; 16,666 vested on May 25, 2018 and 16,667 will vest on May 25, 2019 and 2020. F4 · derivative.expiration_date: These restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:36 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Tax withholdingCommon Stock | 3,725 | $11.57 | $43,098.25 |
DisclosureSEC source: 0001077183-18-000026 · wf-form4_152763335346523.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,491 F1 · shares: Shares withheld by NeoGenomics Laboratories, Inc. to satisfy the tax obligations in connection with the May 25, 2018 vesting of restricted stock. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:36 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000026 · wf-form4_152763335346523.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · derivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 13,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015, Jennifer Balliet was granted 120,000 stock options,these options vest ratably over the first three anniversary dates of the grant date. On March 26, 2018, 7,000 of these options were exercised leaving a balance of 113,000 options. Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 6,500 | $11.26 | $73,190.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 6,500 | $11.21 | $72,865.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 13,000 | $4.78 | $62,140.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | OtherStock Option (Right to Buy) · Derivative | 21,666 | $7.52 Strike: $7.52 | $162,928.32 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 8 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,334 Underlying: Common Stock · 21,666 shares Expires 2022-04-28 F2 · derivative.exercise_date: On April 28, 2017, Mr. Ross was granted 65,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 21,666 of these options in May 2018, leaving a balance of 43,334 options. Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | OtherStock Option (Right to Buy) · Derivative | 26,666 | $7.15 Strike: $7.15 | $190,661.90 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 7 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 26,666 shares Expires 2021-04-20 F1 · derivative.exercise_date: On April 20, 2016, Mr. Ross was granted 40,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 26,666 of these options in May 2018, leaving a balance of 13,334 options. Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | OtherStock Option (Right to Buy) · Derivative | 33,667 | $4.78 Strike: $4.78 | $160,928.26 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 6 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,667 shares Expires 2020-05-06 Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | SaleCommon Stock | 81,999 | $10.78 | $883,949.22 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | Exercise / conversionCommon Stock | 21,666 | $7.52 | $162,928.32 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 4 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | Exercise / conversionCommon Stock | 26,666 | $7.15 | $190,661.90 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 3 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | Exercise / conversionCommon Stock | 33,667 | $4.78 | $160,928.26 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 2 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| March 28, 2018 Filed Mar 28, 2018 20:57 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Disposition to issuerCommon Stock | 7,000 | $8.20 | $57,400.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 28, 2018 Filed Mar 28, 2018 20:57 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 7,000 | $4.78 | $33,460.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:56 UTC |
Virag SharonChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 192,500 | $8.22 Strike: $8.22 | $1,582,350.00 |
DisclosureSEC source: 0001628280-18-003727 · wf-form4_152227057455907.xml · derivative · entry 1 Virag Sharon · CIK 0001576811 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2023-03-27 F1 · derivative.exercise_date: On March 27, 2018, Ms. Virag was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first three anniversary dates of the grant date. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 20:57 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $4.78 Strike: $4.78 | $33,460.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · derivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 7,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015, Jennifer Balliet was granted stock options, these options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:59 UTC |
McKenzie Kathryn BPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 48,000 | $8.03 Strike: $8.03 | $385,440.00 |
DisclosureSEC source: 0001209191-18-014684 · doc4.xml · derivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2023-02-26 F2 · derivative.exercise_date: On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:57 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantStock Option (Right to Buy) · Derivative | 72,500 | $8.03 Strike: $8.03 | $582,175.00 |
DisclosureSEC source: 0001209191-18-014681 · doc4.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2023-02-26 F7 · derivative.exercise_date: On February 26, 2018, Jennifer Balliet was granted 72,500 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:54 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantStock Option (Right to Buy) · Derivative | 288,500 | $8.03 Strike: $8.03 | $2,316,655.00 |
DisclosureSEC source: 0001209191-18-014680 · doc4.xml · derivative · entry 6 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,500 Underlying: Common Stock · 288,500 shares Expires 2023-02-26 F7 · derivative.exercise_date: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:47 UTC |
CARDOZA GEORGEChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 192,500 | $8.03 Strike: $8.03 | $1,545,775.00 |
DisclosureSEC source: 0001209191-18-014677 · doc4.xml · derivative · entry 8 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2023-02-26 F8 · derivative.exercise_date: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:45 UTC | GrantStock Option(Right to Buy) · Derivative | 72,500 | $8.03 Strike: $8.03 | $582,175.00 |
DisclosureSEC source: 0001209191-18-014676 · doc4.xml · derivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2023-02-26 F4 · derivative.exercise_date: On February 26, 2018, Mr. Ross was granted 72,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
|
| February 26, 2018 Filed Feb 28, 2018 23:40 UTC |
VAN OORT DOUGLAS MChairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 636,000 | $8.03 Strike: $8.03 | $5,107,080.00 |
DisclosureSEC source: 0001209191-18-014675 · doc4.xml · derivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,000 Underlying: Common Stock · 636,000 shares Expires 2023-02-26 F8 · derivative.exercise_date: On February 26, 2018, Mr. VanOort was granted 636,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:37 UTC |
BRODIE STEVEN G.Vice President of Operations
|
GrantStock Option (Right to Buy) · Derivative | 58,000 | $8.03 Strike: $8.03 | $465,740.00 |
DisclosureSEC source: 0001209191-18-014673 · doc4.xml · derivative · entry 6 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2023-02-26 F5 · derivative.exercise_date: On February 26, 2018, Dr. Brodie was granted 58,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Mar 28, 2018 20:58 UTC Amendment |
VAN OORT DOUGLAS MChairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 500,000 | $8.03 Strike: $8.03 | $4,015,000.00 |
DisclosureSEC source: 0001628280-18-003730 · wf-form4a_152227067929061.xml · derivative · entry 1 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2023-02-26 F1 · shares: The number of shares of common stock covered by this stock option grant exceeded a limitation applicable to equity awards under the Amended and Restated Equity Incentive Plan and 136,000 excess options were rescinded. This Amended Form 4 reflects the corrected number of stock options granted. Except as otherwise stated above, the vesting and other terms and conditions of the stock option will remain unchanged. F2 · derivative.exercise_date: On February 26, 2018, Mr. VanOort was granted stock options; these stock options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 23:35 UTC |
GENERAL ELECTRIC CO10% owner
|
OtherSeries A Convertible Preferred Stock · Derivative | 264,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-000362 · doc4.xml · derivative · entry 1 GENERAL ELECTRIC CO · CIK 0000040545 · 10% owner GE Medical Systems Information Technologies, Inc. · CIK 0001662667 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,864,000 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: At any time after December 30, 2018, to the extent that the volume weighted average price of the common stock, par value $0.001 per share ("Common Stock") of NeoGenomics, Inc., a Nevada corporation ("NeoGenomics"), equals or exceeds $8.00 per share, as adjusted for standard anti-dilution adjustments, for 30 consecutive trading days, GE Medical Systems Information Technologies, Inc., a Wisconsin corporation ("GE InfoTech"), will be entitled to convert all or any of the shares of Series A Preferred Stock, par value $0.001 per share of NeoGenomics ("Preferred Stock") held by GE InfoTech into Common Stock in accordance with the terms of the Preferred Stock. In addition, if any Preferred Stock remains issued and outstanding on December 30, 2025, such Preferred Stock will automatically convert into Common Stock pursuant to the terms of the Preferred Stock. F2 · derivative.exercise_price: The conversion price for the Preferred Stock was initially set at $7.50 per share, which conversion price is subject to adjustment from time to time for stock splits, reclassifications, and certain distributions by NeoGenomics. F3 · kind: This Form 4 is being filed in connection with the payment of paid-in-kind dividends as provided for by the terms of the Preferred Stock ("PIK Dividends"), which payment is exempt from Section 16 of the Securities Exchange Act of 1934 under SEC Rule 16a-9 and/or Rule 16b-b(6). F3 · shares: This Form 4 is being filed in connection with the payment of paid-in-kind dividends as provided for by the terms of the Preferred Stock ("PIK Dividends"), which payment is exempt from Section 16 of the Securities Exchange Act of 1934 under SEC Rule 16a-9 and/or Rule 16b-b(6). F3 · price: This Form 4 is being filed in connection with the payment of paid-in-kind dividends as provided for by the terms of the Preferred Stock ("PIK Dividends"), which payment is exempt from Section 16 of the Securities Exchange Act of 1934 under SEC Rule 16a-9 and/or Rule 16b-b(6). F4 · price: As provided for by the terms of the Preferred Stock, PIK Dividends accrue and are paid in kind on shares of Preferred Stock at the specified PIK Dividend rate multiplied by the then-effective liquidation preference. On December 31, 2017, PIK Dividends were paid in accordance with the terms of the Preferred Stock. As of such date, the aggregate effective liquidation preference of the Preferred Stock reported in this Form 4 was $51,480,000. F5 · price: Based on the initial conversion price and the liquidation preference of the Preferred Stock in effect on the date of this filing, 6,864,000 shares of Common Stock could have been issued had the Preferred Stock been convertible, and converted in full, on such date. Based on the initial conversion price and assuming that all PIK Dividends are paid pursuant to the terms of the Preferred Stock, it is expected that a total of 11,448,954 shares of Common Stock would be issued if all of the shares of Preferred Stock remain outstanding through December 30, 2025 and are converted in full on such date. F1 · derivative.exercise_date: At any time after December 30, 2018, to the extent that the volume weighted average price of the common stock, par value $0.001 per share ("Common Stock") of NeoGenomics, Inc., a Nevada corporation ("NeoGenomics"), equals or exceeds $8.00 per share, as adjusted for standard anti-dilution adjustments, for 30 consecutive trading days, GE Medical Systems Information Technologies, Inc., a Wisconsin corporation ("GE InfoTech"), will be entitled to convert all or any of the shares of Series A Preferred Stock, par value $0.001 per share of NeoGenomics ("Preferred Stock") held by GE InfoTech into Common Stock in accordance with the terms of the Preferred Stock. In addition, if any Preferred Stock remains issued and outstanding on December 30, 2025, such Preferred Stock will automatically convert into Common Stock pursuant to the terms of the Preferred Stock. F1 · derivative.expiration_date: At any time after December 30, 2018, to the extent that the volume weighted average price of the common stock, par value $0.001 per share ("Common Stock") of NeoGenomics, Inc., a Nevada corporation ("NeoGenomics"), equals or exceeds $8.00 per share, as adjusted for standard anti-dilution adjustments, for 30 consecutive trading days, GE Medical Systems Information Technologies, Inc., a Wisconsin corporation ("GE InfoTech"), will be entitled to convert all or any of the shares of Series A Preferred Stock, par value $0.001 per share of NeoGenomics ("Preferred Stock") held by GE InfoTech into Common Stock in accordance with the terms of the Preferred Stock. In addition, if any Preferred Stock remains issued and outstanding on December 30, 2025, such Preferred Stock will automatically convert into Common Stock pursuant to the terms of the Preferred Stock. F4 · derivative.underlying_shares: As provided for by the terms of the Preferred Stock, PIK Dividends accrue and are paid in kind on shares of Preferred Stock at the specified PIK Dividend rate multiplied by the then-effective liquidation preference. On December 31, 2017, PIK Dividends were paid in accordance with the terms of the Preferred Stock. As of such date, the aggregate effective liquidation preference of the Preferred Stock reported in this Form 4 was $51,480,000. F5 · derivative.underlying_shares: Based on the initial conversion price and the liquidation preference of the Preferred Stock in effect on the date of this filing, 6,864,000 shares of Common Stock could have been issued had the Preferred Stock been convertible, and converted in full, on such date. Based on the initial conversion price and assuming that all PIK Dividends are paid pursuant to the terms of the Preferred Stock, it is expected that a total of 11,448,954 shares of Common Stock would be issued if all of the shares of Preferred Stock remain outstanding through December 30, 2025 and are converted in full on such date. F6 · ownership.direct: GE InfoTech is a wholly owned subsidiary of General Electric Company, a New York corporation ("General Electric"). General Electric disclaims beneficial ownership of the Common Stock and the Preferred Stock held by GE InfoTech except to the extent of its pecuniary interest, and the filing of this Form 4 shall not be deemed an admission that General Electric is the beneficial owner of any equity securities of NeoGenomics for purposes of Section 16 or any other purpose. F6 · ownership.nature: GE InfoTech is a wholly owned subsidiary of General Electric Company, a New York corporation ("General Electric"). General Electric disclaims beneficial ownership of the Common Stock and the Preferred Stock held by GE InfoTech except to the extent of its pecuniary interest, and the filing of this Form 4 shall not be deemed an admission that General Electric is the beneficial owner of any equity securities of NeoGenomics for purposes of Section 16 or any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 21:38 UTC |
JONES STEVEN CExecutive Vice President
|
GiftCommon Stock | 20,000 | $9.06 | $181,200.00 |
DisclosureSEC source: 0001209191-17-065689 · doc4.xml · nonDerivative · entry 2 JONES STEVEN C · CIK 0001518732 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,251 Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 20:03 UTC |
McKenzie Kathryn BPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $9.07 Strike: $9.07 | $226,750.00 |
DisclosureSEC source: 0001209191-17-057606 · doc4.xml · derivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-10-18 F1 · derivative.exercise_date: On October 18, 2017, Ms. McKenzie was granted an option to purchase 25,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
OtherStock Option (Right to Buy) · Derivative | 15,000 | $3.45 Strike: $3.45 | $51,750.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-03-05 F3 · derivative.exercise_date: On March 5, 2014, Jennifer Balliet was granted 15,000 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
OtherStock Option (Right to Buy) · Derivative | 7,500 | $3.76 Strike: $3.76 | $28,200.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · derivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-04-16 F2 · derivative.exercise_date: On April 16, 2013, Jennifer Balliet was granted 7,500 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Disposition to issuerCommon Stock | 22,500 | $9.38 | $211,050.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Average price of shares sold Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 7,500 | $3.76 | $28,200.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 15,000 | $3.45 | $51,750.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Oct 3, 2017 21:19 UTC |
HANNAH ALISON L.Director
|
OtherStock Option (Right to Buy) · Derivative | 6,667 | $6.66 Strike: $6.66 | $44,402.22 |
DisclosureSEC source: 0001209191-17-055258 · doc4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 6,667 shares Expires 2020-07-15 F1 · derivative.exercise_date: On July 15, 2015 Alison Hannah was granted 10,000 stock options, the options vest ratably on the next three anniversary dates of the grant date. On 8/9/2017 6,667 of these options were exercised leaving a balance of 3,333. Read SEC document |
| August 09, 2017 Filed Oct 3, 2017 21:19 UTC |
HANNAH ALISON L.Director
|
Exercise / conversionCommon Stock | 6,667 | $6.66 | $44,402.22 |
DisclosureSEC source: 0001209191-17-055258 · doc4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:25 UTC |
HANNAH ALISON L.Director
|
PurchaseCommon Stock | 20,000 | $9.19 | $183,800.00 |
DisclosureSEC source: 0001209191-17-046748 · doc4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,782 F1 · price: Represents the average purchase price of shares purchased on July 27, 2017. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 01:25 UTC |
BRODIE STEVEN G.Vice President of Operations
|
OtherStock Option (Right to Buy) · Derivative | 6,666 | $3.45 Strike: $3.45 | $22,997.70 |
DisclosureSEC source: 0001209191-17-044259 · doc4.xml · derivative · entry 2 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 6,666 shares Expires 2019-03-05 F1 · derivative.exercise_date: On March 5, 2014, Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date. On July 5, 2017, Dr. Brodie exercised 6,666 options leaving a balance of 13,334. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 01:25 UTC |
BRODIE STEVEN G.Vice President of Operations
|
Exercise / conversionCommon Stock | 6,666 | $3.45 | $22,997.70 |
DisclosureSEC source: 0001209191-17-044259 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 22:09 UTC |
JONES STEVEN CExecutive Vice President
|
OtherCommon Stock | 190,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-042170 · doc4.xml · nonDerivative · entry 6 JONES STEVEN C · CIK 0001518732 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self as Trustee for Steven and Carisa Jones 401k and Trust Disclosed balance after: 190,000 F2 · price: Transaction represents non-market transfer from Steven and Carisa Jones Defined Benefit Plan to Steven and Carisa Jones 401k Plan and Trust Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 22:09 UTC |
JONES STEVEN CExecutive Vice President
|
OtherCommon Stock | 190,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-042170 · doc4.xml · nonDerivative · entry 5 JONES STEVEN C · CIK 0001518732 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self as Trustee for Steven and Carisa Jones Defined Benefit Plan and Trust Disclosed balance after: 190,000 F2 · price: Transaction represents non-market transfer from Steven and Carisa Jones Defined Benefit Plan to Steven and Carisa Jones 401k Plan and Trust Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:32 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 10,723 | $8.49 | $91,038.27 |
DisclosureSEC source: 0001209191-17-041859 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 20:39 UTC | SaleCommon stock | 45,833 | $7.79 | $357,039.07 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 6 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.